PCM
FLXN

Peregrine Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Peregrine Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-478,109
Closed -$5.52M – 360
2020
Q4 		$5.52M Sell
478,109
-43,473
-8% -$505K 0.1% 252
2020
Q3 		$5.43M Sell
521,582
-49,606
-9% -$608K 0.14% 226
2020
Q2 		$7.51M Sell
571,188
-19,110
-3% -$198K 0.21% 148
2020
Q1 		$4.65M Buy
590,298
+1,930
+0.3% +$29.1K 0.17% 174
2019
Q4 		$12.2M Sell
588,368
-193,009
-25% -$3.25M 0.31% 131
2019
Q3 		$10.7M Buy
781,377
+25,603
+3% +$304K 0.29% 140
2019
Q2 		$9.3M Sell
755,774
-1,811
-0.2% -$20.9K 0.23% 167
2019
Q1 		$9.46M Sell
757,585
-15,460
-2% -$207K 0.24% 159
2018
Q4 		$8.75M Sell
773,045
-4,730
-0.6% -$74.2K 0.25% 149
2018
Q3 		$14.6M Buy
777,775
+111,615
+17% +$2.56M 0.34% 129
2018
Q2 		$17.2M Buy
666,160
+33,890
+5% +$879K 0.43% 106
2018
Q1 		$14.2M Sell
632,270
-30,605
-5% -$747K 0.35% 120
2017
Q4 		$16.6M Buy
662,875
+67,664
+11% +$1.66M 0.39% 106
2017
Q3 		$14.4M Sell
595,211
-114,052
-16% -$2.68M 0.35% 118
2017
Q2 		$14.3M Sell
709,263
-3,368
-0.5% -$70.2K 0.36% 109
2017
Q1 		$19.2M Sell
712,631
-24,256
-3% -$495K 0.49% 71
2016
Q4 		$14M Buy
736,887
+13,982
+2% +$267K 0.36% 111
2016
Q3 		$14.1M Buy
+722,905
New +$12.2M 0.37% 113

Other funds holding FLXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Peregrine Capital Management's FLXN Position: Q1 2021 in Review

Peregrine Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2021, closing a stake of 478,109 shares — an estimated $5.52M sold.

Peregrine Capital Management first reported a position in FLXN in Q3 2016 and held it in 18 quarters. The position peaked at $19.2M in Q1 2017. 145 funds tracked by Wall St. Rank hold FLXN as of Q1 2021.

  • Peregrine Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Peregrine Capital Management sold 478,109 Flexion Therapeutics, Inc. shares in Q1 2021, an estimated $5.52M.
  • Peregrine Capital Management first reported a position in Flexion Therapeutics, Inc. in Q3 2016 and held it in 18 quarters.
  • Peregrine Capital Management's Flexion Therapeutics, Inc. position peaked at $19.2M in Q1 2017.
  • 145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2021.

Based on Peregrine Capital Management's 13F filing for Q1 2021, filed 11 May 2021.